Anavex Life Sciences Corp. (NASDAQ: AVXL) is one of 93 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Anavex Life Sciences Corp. to related companies based on the strength of its earnings, valuation, analyst recommendations, institutional ownership, profitability, risk and dividends.

Insider and Institutional Ownership

24.4% of Anavex Life Sciences Corp. shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 11.6% of Anavex Life Sciences Corp. shares are owned by company insiders. Comparatively, 19.6% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Anavex Life Sciences Corp. has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Anavex Life Sciences Corp.’s competitors have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.

Profitability

This table compares Anavex Life Sciences Corp. and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anavex Life Sciences Corp. N/A -95.68% -84.88%
Anavex Life Sciences Corp. Competitors -919.42% -189.81% -26.55%

Earnings and Valuation

This table compares Anavex Life Sciences Corp. and its competitors gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Anavex Life Sciences Corp. N/A -$15.61 million -10.59
Anavex Life Sciences Corp. Competitors $223.74 million $57.84 million -0.98

Anavex Life Sciences Corp.’s competitors have higher revenue and earnings than Anavex Life Sciences Corp.. Anavex Life Sciences Corp. is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and price targets for Anavex Life Sciences Corp. and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences Corp. 0 0 3 0 3.00
Anavex Life Sciences Corp. Competitors 164 548 1210 16 2.56

Anavex Life Sciences Corp. currently has a consensus target price of $13.67, indicating a potential upside of 230.91%. As a group, “Biotechnology” companies have a potential upside of 55.35%. Given Anavex Life Sciences Corp.’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Anavex Life Sciences Corp. is more favorable than its competitors.

Anavex Life Sciences Corp. Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.